Adrecizumab in Cardiogenic Shock

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

Also called NCT03989531

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
Dr. med. Mahir Karakas (from the registry)
Registry
  • NCT NCT03989531
Other papers using this trial's data
  • Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial The Lancet. Respiratory medicine, 2022-03 DOI, PubMed 34895483

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03989531. Randomized; quadruple masking; primary purpose treatment. Start 2019-04-04 (actual); primary completion 2021-04-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adrecizumab in Cardiogenic Shock
Acronym
ACCOST-HH
Condition
Cardiogenic Shock
Condition
Endothelial Dysfunction
Intervention (Biological)
Adrecizumab
Intervention (Drug)
Placebo
Lead sponsor
Dr. med. Mahir Karakas (class: other)

Record details

Record id
cardio:ct-nct03989531
Content hash
259e166a4a95af0c53674665ee7f5d6dee9acffdb93146164156ba52d9c01653